Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)

Inclusion Criteria: * Only subjects for whom the investigator believes the requirements of the protocol will be complied with will be enrolled in the study * A male or female adult \>= 40 years of age * Written informed consent to be obtained from the subject prior to study entry * No history of diphtheria or tetanus toxoid containing vaccination in the last 20 years, including those who have never been vaccinated and those with an unknown vaccination status. * Free of obvious health problems as established by medical history and clinical examination before entering into the study. * subject should not be pregnant or plan to become pregnant. Exclusion Criteria: * Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period * Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. * Major congenital defects or serious chronic illness. * History of any neurologic disorders or seizures * Acute disease at the time of enrolment. * Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period. * Pregnant or lactating female * Female planning to become pregnant or planning to discontinue contraceptive precautions * Previous vaccination with a meningococcal-conjugate vaccine, Prevenar™ or other experimental conjugated pneumococcal vaccines * History of allergic disease or reactions likely to be exacerbated by any component of the vaccine(s). * Any confirmed or suspected immunosuppressive or immunodeficient condition